ClinicalTrials.Veeva
Menu

Find clinical trials for Ovarian Cancer in Nashville, TN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Cancer
Carcinoma
Endometrial Cancer
Fallopian Tube Cancer
Breast Cancer
Triple Negative Breast Cancer

Ovarian Cancer trials near Nashville, TN, USA:

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...

Active, not recruiting
Relapsed Ovarian Cancer
Following Complete or Partial Response to Platinum Based Chemotherapy
Drug: Placebo to match olaparib 300mg
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Nashville, Tennessee, United States and 125 other locations

A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation (RAMP 201)

the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian...

Active, not recruiting
Low Grade Ovarian Serous Adenocarcinoma
Ovarian Cancer
Drug: avutometinib (VS-6766) and defactinib
Drug: avutometinib (VS-6766)

Phase 2

Verastem

Nashville, Tennessee, United States and 46 other locations

A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer

Phase 1 trial to study the safety, pharmacokinetic and Preliminary Efficacy of STRO-002 in combination with Bevacizumab.

Enrolling
Ovary Cancer
Ovarian Carcinoma
Drug: STRO-002
Drug: Bevacizumab

Phase 1

Sutro Biopharma

Nashville, Tennessee, United States and 5 other locations

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

of alpelisib and olaparib compared with single agent cytotoxic chemotherapy in patients with platinum resistant or refractory high-grade serous ovarian...

Active, not recruiting
Ovarian Cancer
Drug: Alpelisib
Drug: Pegylated liposomal doxorubicin (PLD)

Phase 3

Novartis
Novartis

Nashville, Tennessee, United States and 113 other locations

A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian...

Enrolling
Solid Tumor
Ovarian Cancer
Drug: CUSP06

Phase 1

OnCusp Therapeutics

Nashville, Tennessee, United States and 6 other locations

A Study of ZN-c3 in Patients With Ovarian Cancer

This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and phar...

Enrolling
Solid Tumor
Epithelial Ovarian Cancer
Drug: Pegylated liposomal doxorubicin
Drug: Paclitaxel

Phase 1

K-Group Beta

Nashville, Tennessee, United States and 23 other locations

Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

of REGN4018 can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus* The study will ...

Enrolling
Recurrent Primary Peritoneal Cancer
Recurrent Ovarian Cancer
Drug: REGN4018
Drug: Sarilumab

Phase 1, Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Nashville, Tennessee, United States and 49 other locations

A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)

Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)....

Active, not recruiting
Relapsed Solid Tumors
Refractory Solid Tumors
Drug: KB-0742

Phase 1, Phase 2

Kronos Bio

Nashville, Tennessee, United States and 24 other locations

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST)

Ovarian cancer is a heterogeneous disease, characterized by complex molecular and genetic changes. The high expression of vascular ...

Active, not recruiting
Ovarian Neoplasms
Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
Drug: Dostarlimab-Placebo
Drug: Standard of care

Phase 3

Tesaro
Tesaro

Nashville, Tennessee, United States and 202 other locations

PRO1184 for Advanced Solid Tumors (PRO1184-001)

This study will test the safety, including side effects, and determine the characteristics of a drug called PRO1184 in participants with solid tumors...

Enrolling
Hormone Receptor-positive/Her2 Negative Breast Cancer
High Grade Serous Ovarian Cancer
Drug: PRO1184 intravenous infusion of PRO1184
Drug: PRO1184

Phase 1, Phase 2

Genmab
Genmab

Nashville, Tennessee, United States and 31 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems